Hyperthermic intraperitoneal chemotherapy for treating ovarian cancer
| Autor: | Jessica N Pelkowski, Amanda P. Stanton, Tri Dinh, Rose Dorian, Shilpa N. Gajarawala |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Hyperthermia
Oncology medicine.medical_specialty Hyperthermic Intraperitoneal Chemotherapy Carcinoma Ovarian Epithelial Nurse Assisting Cytoreduction Surgical Procedures Internal medicine medicine Carcinoma Humans Pseudomyxoma peritonei Combined Modality Therapy Ovarian Neoplasms business.industry Hyperthermia Induced medicine.disease Quality of Life Peritoneal mesothelioma Female Hyperthermic intraperitoneal chemotherapy Neoplasm Recurrence Local business Ovarian cancer |
| Zdroj: | Journal of the American Academy of Physician Assistants. 34:50-53 |
| ISSN: | 1547-1896 |
| DOI: | 10.1097/01.jaa.0000735800.98948.bb |
| Popis: | Hyperthermic intraperitoneal chemotherapy (HIPEC) has been used for decades as a treatment for disseminated abdominal malignancies, including pseudomyxoma peritonei and peritoneal mesothelioma. HIPEC had been used to treat recurrent ovarian cancer only when curative options were lacking, but new data indicate that it may be suitable as a primary treatment for patients with late-stage epithelial ovarian cancer, increasing the recurrence-free time interval and improving quality of life. However, treatment can be challenging because of patient trauma from surgery, combined with the toxicity and high temperature of the chemotherapeutic agents. This article reviews HIPEC and its targeted intraoperative and postoperative management. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|